ONCODESIGN announced that it is furthering its cooperation with Eisai Co. Ltd. with the signing of a new services agreement. This services agreement aims to evaluate the anti-tumor efficacy of Eisai new compounds, alone or in combination with standards of care, on a panel of Patient-Derived Xenografts (PDX) of breast cancer developed specifically by Oncodesign between 2012 and 2017. The methodology used in these preclinical pharmacology studies is based on the Single Mouse Trial (SMT) format, where each preclinical subject represents one patient receiving different treatments. The program will include a total of over 200 investigational arms. The results will help position the use of these new compounds during early clinical phases in sub-populations of patients selected on histological and genetic biomarkers determined jointly with Oncodesign. Oncodesign and Eisai expect to publish shortly the results of previous joint scientific work on the demonstration of the early efficacy of eribulin mesylate on breast tumors of different histological types. This work, conducted with the breast cancer PDX collection developed by Oncodesign, helped characterize genetic biomarkers of the response to treatment.